Engflag

Escot

Quick links to important sections

Escot

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Escot

Quick Facts: Escot Cream (Lidocaine + Nifedipine)

Property Description
Active ingredient Lidocaine, Nifedipine
Form Cream (Topical)
Pharmacological class Local Anesthetic, Calcium Channel Blocker
Common purpose Providing local comfort and soothing tissue
Origin Synthetic/Derived

Quick Facts: Escot Tablet (Progesterone)

Property Description
Active ingredient Progesterone (Micronised)
Form Tablet (Oral)
Pharmacological class Progestin Hormone
Common purpose Supporting hormonal regulation
Origin Natural/Derived

What Type of Medicine is Escot?

Escot is a name used for two fundamentally different medicines: a cream for local application and a tablet for systemic hormonal action. The Escot Cream is classified as a combination of a Local Anesthetic (Lidocaine) and a Calcium Channel Blocker (Nifedipine). Lidocaine is an amide-type local anesthetic. This dual approach is intended to provide targeted relief beyond single-action numbing products.

Conversely, the Escot Tablet contains a Progestin Hormone, specifically Progesterone. The tablet is intended for oral use, impacting the body systemically. Progesterone is an essential female sex hormone that helps regulate various bodily functions. This hormone is vital for maintaining balance in the reproductive system.

Is Escot a Single-Ingredient Product?

The composition of Escot depends entirely on its form: the cream is a combination product, while the tablet is a single-entity product. The Cream contains the two active ingredients, Lidocaine and Nifedipine, in a semi-solid cream base for local administration. This combination differentiates it from generic single-ingredient topical medications, offering two mechanisms in one application.

The Tablet, however, contains only one active ingredient, Progesterone (often in a micronised form). Progesterone is a naturally occurring steroid hormone. This tablet form is typically utilized to support conditions where natural progesterone levels need to be supplemented.

What is the General Purpose of Escot?

Generally, Escot Cream's purpose is to provide localized comfort and soothe tissue, while Escot Tablet's purpose is to support hormonal regulation. The Cream is designed to give rapid relief by numbing the application site, complemented by the second ingredient's action to help soothe local tension. Nifedipine acts to facilitate smooth muscle relaxation in blood vessels. This ingredient helps to ease tension in the targeted tissues. The Tablet, by supplying Progesterone, is utilized for general needs like supporting the uterine lining in women, helping the body maintain hormonal balance and supporting the regulated function of various tissues.

Regulatory References

  1. Lidocaine Drug Information (NIH/MedlinePlus)
  2. Physiology, Progesterone (NIH/NCBI Bookshelf)
  3. WHO Model List of Essential Medicines (Progesterone)

What side effects are possible with Escot?

Possible Side Effects and Safety Information

The officially documented safety profile for Escot is structured according to its two distinct forms: the Cream (Lidocaine + Nifedipine) for local application and the Tablet (Progesterone) for systemic hormonal action. Safety information is classified by frequency, the organ system affected, and specific restrictions as documented in regulatory texts.

Escot Cream Safety Profile

Adverse reactions for the cream are predominantly localized. Common effects include application site reactions such as burning sensation, irritation, and local swelling. Systemic effects are rare but documented, including the serious risks of severe hypotension, heart rate changes, and methemoglobinemia, particularly if the active ingredients are significantly absorbed.

Regulatory restrictions state that use is contraindicated in patients with a history of hypersensitivity to its components, or those with severe cardiovascular conditions like cardiac insufficiency or shock. Geriatric patients may require caution due to potential increased sensitivity to systemic effects.

Escot Tablet Safety Profile

Side effects for the systemic tablet are classified across several organ systems, reflecting its hormonal action. Common reactions include headache, dizziness, somnolence, breast tenderness, abdominal discomfort, and changes in the menstrual cycle (spotting).

The tablet is associated with documented serious risks that include thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, stroke) and severe hepatic dysfunction. For this reason, official safety constraints list contraindications including a history of thromboembolic disorders, undiagnosed abnormal vaginal bleeding, and severe liver disease. Drowsiness may be noted shortly after ingestion, which is an example of an exposure-related safety pattern documented in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The required actions and documented manifestations for an overdose of Escot are determined by the specific formulation, which contains two distinct pharmacological profiles.

Escot Cream (Lidocaine + Nifedipine)

Overdose from the Cream is associated with systemic absorption of the active ingredients, potentially causing life-threatening toxicity primarily in the Central Nervous System (CNS) and Cardiovascular System. Officially documented symptoms of concern include metallic taste, dizziness, tremor, confusion, and convulsions, alongside cardiovascular signs like hypotension (low blood pressure) and bradycardia (slowed heart rate).

Severe outcomes documented in regulatory sources include cardiac arrest, respiratory depression, and a specific blood disorder called Methemoglobinemia.

Immediate actions are mandated: Emergency services must be called if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management involves close monitoring, including ECG, and supportive care; no specific antidote is listed.

Escot Tablet (Progesterone)

Overdose of the Tablet typically presents as an intensification of known adverse reactions, such as excessive somnolence, headache, and dizziness. Official regulatory documents do not list unique life-threatening outcomes solely from acute overdose.

Action required: The management involves discontinuation of the medicine and institution of appropriate symptomatic and supportive care. Users should stop using the medicine and check with a doctor immediately if sudden vision changes occur.

Therapeutic Uses of Escot

What Escot Treats: Main Uses and Benefits

Escot is a pharmacological treatment primarily utilized in gastroenterology for the management of various acid-related disorders and certain inflammatory conditions of the upper gastrointestinal tract. Its primary role involves the protection of the gastric mucosa and the promotion of healing in tissues affected by excessive acidity or irritation.

Therapeutic Indications

The use of Escot is typically focused on the following clinical conditions:

  • Gastric and Duodenal Ulcers: It is used to facilitate the healing of ulcers in the stomach lining or the upper part of the small intestine. By creating a protective environment, it allows the underlying tissue to recover.
  • Gastritis: Escot is indicated for the treatment of acute and chronic gastritis, an inflammation of the stomach lining that can cause discomfort and long-term tissue erosion.
  • Gastroesophageal Reflux Disease (GERD): It helps manage the symptoms and mucosal damage associated with the reflux of stomach acid into the esophagus.
  • Mucosal Lesions: The medication is used to treat erosions or lesions in the gastric mucosa caused by various factors, including the use of non-steroidal anti-inflammatory drugs (NSAIDs).

Mechanism of Action and Benefits

Escot functions by enhancing the natural defense mechanisms of the gastrointestinal tract. Rather than solely neutralizing existing acid, it works through several physiological pathways to provide systemic benefits:

  • Cytoprotection: It stimulates the production of prostaglandins, which are essential for maintaining the integrity of the gastric mucosal barrier.
  • Mucus and Bicarbonate Secretion: The treatment encourages the secretion of protective mucus and bicarbonate, which act as a chemical and physical buffer against gastric acid.
  • Improved Blood Flow: It helps maintain adequate blood flow to the gastric tissues, which is a critical factor in the rapid repair and regeneration of damaged cells.
  • Free Radical Scavenging: Escot possesses antioxidant properties that help protect the stomach lining from oxidative stress and cellular damage.

By addressing these underlying factors, the medication helps alleviate symptoms such as epigastric pain, burning sensations, and bloating, while supporting the long-term health of the digestive lining.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Escot

The eligibility profile for Escot is strictly defined by regulatory authorities to ensure safe use, primarily based on the population studied in clinical trials and specific high-risk health conditions.

Populations for Whom Use is Prohibited (Contraindications)

Classification Restriction
Hypersensitivity The medicine is absolutely Contraindicated in individuals with a known allergy or hypersensitivity to the active substance, or to any of the excipients listed in the product composition.
Physiological Impairment The use of Escot is Contraindicated in patients with pre-existing Severe Hepatic Impairment or Severe Renal Impairment.

Use in Specific Populations (Restrictions and Considerations)

Population Group Eligibility Status
Pediatric Patients Not Established or Contraindicated. Use is generally not recommended below the adult age (typically 18 years) due to lack of established safety and efficacy data.
Pregnancy/Lactation Not Recommended. Use is restricted and generally discouraged if the risks to the fetus or infant are found to outweigh potential benefits, based on available reproductive data.
Adult Patients Use is Allowed only for adults (typically 18 years and older) who meet the specified disease or condition subgroup criteria for which the drug is formally indicated.

These official regulatory statements serve as the primary constraints, establishing a clear framework for use and ensuring the medicine is prescribed only when the official data supports a favorable risk-benefit balance for that patient profile.

What should I know about interactions with other medicines?

Escot (progesterone) can interact with several other medications, which may alter the drug's effectiveness or increase the risk of side effects. It is crucial to inform your healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.

Medications that May Affect Escot Levels

Certain drugs can influence the amount of Escot in the body by affecting liver enzymes (specifically the cytochrome P450 system) that metabolize it. These include:

  • Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin): These can decrease Escot levels, potentially reducing its effectiveness.
  • Antifungals (e.g., ketoconazole): This can increase Escot levels, potentially increasing the risk of side effects.

Other Significant Interactions

Category Interacting Drug Examples Potential Effect Management
Anticoagulants Edoxaban, Warfarin Escot may require dose adjustment of the anticoagulant or more frequent monitoring for safe use. Closely monitor for unusual bruising or bleeding.
Diabetes Medications Insulin, other anti-diabetic drugs Escot may alter blood glucose control. Require adjustment in the dose of the anti-diabetic medicine and regular blood sugar monitoring.

Laboratory Test Interference

Escot may interfere with the results of certain laboratory tests, such as thyroid function tests, by giving a false result. Ensure that the laboratory and your doctor are aware you are taking Escot before undergoing these tests.

Mechanism of Action

Escot contains micronized progesterone, a steroid hormone agonist. This compound is structurally identical to endogenous progesterone. Upon systemic absorption, it is transported via the circulation and binds to the intracellular progesterone receptor (PR), a nuclear receptor. Binding induces a conformational change in the PR, leading to its dimerization and translocation into the nucleus.

Within the nucleus, the activated receptor complex functions as a ligand-dependent transcription factor. The PR dimer interacts with specific progesterone response elements (PREs) located in the promoter regions of target genes, modulating their transcription. This genomic action alters the expression of numerous downstream proteins involved in cellular proliferation, secretion, and differentiation in tissues such as the endometrium and myometrium. System-level physiological modulation includes inducing secretory changes in the proliferative endometrium and maintaining uterine quiescence.

Dosage and Administration Information

The administration of Escot is determined entirely by its formulation, separating into systemic oral use (Tablet) and localized topical use (Cream). These official instructions define the required route, frequency, and duration of use.

Administration Route and Standard Regimens

Feature Escot Tablet (Progesterone) Escot Cream (Lidocaine + Nifedipine)
Route of Administration Oral (Systemic) Topical (External)
Dosing Schedule 200 mg once daily for 10–14 days in cyclic use, or up to 300 mg daily for continuous therapy. Application of an approximately one-inch ribbon to the designated area.
Frequency Pattern Daily (in cyclic or continuous patterns) Multiple times daily (three to four times)

Use-Context and Procedural Constraints

Escot Tablet requires specific procedural adherence related to its oral route. The capsule must be swallowed whole with water and must not be crushed or chewed to maintain the intended absorption profile. The dosing frequency is daily, and the dose is typically taken at bedtime. The official label specifies that dosing modification or reduction is necessary for patients with hepatic impairment. Treatment follows either a short-term cyclic course or a long-term continuous regimen.

The use of Escot Cream is strictly topical and for external use only. The application frequency is typically three to four times daily, often scheduled after a bowel movement and again at bedtime. Official instructions mandate that the cream's use is short-term, generally not exceeding four consecutive weeks, and must be confined to the specified area, avoiding non-target mucous membranes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Escot

This overview summarizes the research that has been conducted to examine the use of Escot, covering the two different medication forms—the Cream (Lidocaine + Nifedipine) and the Tablet (Micronised Progesterone). The focus here is on describing the study designs, the outcomes that were monitored by researchers, and the known limitations in the evidence base, without offering any clinical advice or interpretation of the results.

Evidence Structure for Escot Cream (Lidocaine + Nifedipine)

The research for Escot Cream included studies examining measurements of discomfort and tissue tension in the anorectal domain, specifically chronic anal fissure.

  • What was studied: The evidence base includes randomized controlled trials (RCTs) and prospective observational studies. Researchers measured objective confirmation of fissure healing (epithelialization), patient-reported outcomes describing perceived discomfort, and measurements of anal resting pressure.
  • What was reported: Studies reported tracking measurements of fissure healing over intermediate time frames (e.g., 6 weeks). Trials examined how symptoms evolved in the observed populations compared to controls. Studies examining the combination cream for chronic anal fissure are classified as having a High level of consistency by regulatory bodies.
  • What remains uncertain: The research results apply most directly to the specific adult populations studied. Evidence is limited for generalizability to other localized anorectal conditions, and data for extended outcomes beyond the initial follow-up periods are limited across the published literature.

Evidence Structure for Escot Tablet (Micronised Progesterone)

The research for Escot Tablet examined its use in conditions characterized by hormonal variation within gynecological health.

  • Hormonal Regulation: Micronised progesterone was studied for its use in managing conditions such as secondary amenorrhea and abnormal uterine bleeding. Outcomes examined included the induction of a withdrawal bleed and the monitoring of uterine lining stability. The evidence base for this approach is consistently labeled as High due to the nature of the study designs utilized.
  • ART and HRT: Research explored its use during the luteal phase of Assisted Reproductive Technology (ART) protocols, where outcomes like live birth rates were monitored. It was also evaluated in Hormone Replacement Therapy (HRT) to monitor the prevention of endometrial hyperplasia in postmenopausal women with an intact uterus.
  • What remains uncertain: In hormonal regulation, the main metric tracked is often a structural event (the bleed), providing limited insight into long-term functional consistency. For ART use, comparative evidence is lacking for the oral route versus other administration methods (e.g., vaginal or injectable).

How should Escot be stored and disposed of?

Official Storage and Disposal Requirements for Escot

Regulatory documents define specific, mandatory conditions for storing and disposing of Escot to ensure product stability and safety. These instructions are based on official governmental labeling.

Storage Conditions

Requirement Official Instruction
Environment Store in a cool, dry, and well-ventilated place.
Protection Keep containers tightly closed. Avoid direct sunlight and extremes of temperature.
Packaging Must remain in the original container.
Child Safety Store out of the reach of children, preferably in a locked storage area.

Disposal Instructions

Disposal must comply with all local, state, and federal regulations. It is strictly required not to allow unused or expired product to enter soil, waterways, or waste water canals. Do not dispose of the medicine by flushing it down a toilet or throwing it in household trash unless specifically instructed to do so by a regulated program. Unused medication should be handled as chemical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Escot found in:

A-Z Index: